Special Issue "Amyloid Inhibitors and Modulators"
Deadline for manuscript submissions: 31 August 2019
Dr. Gal Bitan
The abnormal self-assembly of proteins into toxic oligomers and aggregates underlies over 30 diseases called proteinopathies. Though many of these diseases affect the central nervous system, infamous examples are Alzheimer’s and Parkinson’s diseases, others attack a particular organ, such as the pancreas in type-2 diabetes, or are systemic, e.g., light-chain amyloidosis and dialysis-related amyloidosis. As the common characteristic of all of these diseases is the abnormal self-assembly process, developing compounds and biologics that inhibit or otherwise perturb this process is an attractive therapeutic strategy for proteinopathies. Disease-modifying therapy for one rare disease—familial amyloidotic polyneuropathy caused by transthyretin—has become available recently, yet for the major diseases, most notoriously Alzheimer’s disease, the recent history has been of multiple failures, including of high-profile, late-phase clinical trials. This grim status, and the pressure caused by increasing incidence numbers of people affected by Alzheimer’s disease and other proteinopathies have raised several important questions. Are we aiming at the right targets? Are we using the right strategies to obtain effective drugs for proteinopathies? Can we use common strategies for multiple diseases or will we need to tailor specific drugs for specific diseases? Are there advantages to drug candidates hitting multiple targets (e.g., both aggregation and inflammation) or are we creating a difficult optimization challenge when compounds have more than one activity? Is targeting prion-like cell-to-cell spreading more or less important than inhibiting the direct toxicity of amyloidogenic proteins? What are the most important structures to target?
This Special Issue of Molecules focused on “Amyloid Inhibitors and Modulators” aims to address many or all of these questions, presenting a perspective on the current state of research in this field, and including research articles demonstrating a variety of strategies for tackling this difficult and pressing problem.
Dr. Gal Bitan
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alzheimer’s disease
- Parkinson’s disease
- drug discovery
- drug design
- drug development